title: The translation of product concept to bone products: a partnership of therapeutic effectiveness and commercialization.
abstract: The fields of tissue engineering and regenerative medicine have the capacity to substantially impact clinical care through the introduction of new products that can address unmet clinical needs, or significantly improve on present therapies. These products will be developed through the demonstration of therapeutic effectiveness, adequate safety, and meeting regulatory requirements. The technology used in the product will dictate the product development and manufacturing costs; the regulatory pathway; and the time taken to complete clinical trials, gain regulatory approval, and become commercialized. A comparison of the required investment of time and funds, with the potential revenue generated, allows for a determination of the likely commercialization opportunity. Ultimately, the long-term success of a product will be dependent on its clinical effectiveness and commercial viability.
authors.affiliation: Synthasome, Inc., San Diego, California 92109, USA. anthonyratcliffe@synthasome.com
authors.forename: Anthony
authors.initials: A
authors.lastname: Ratcliffe
mesh_terms: D001842:Bone and Bones / Q000502:physiology*; D003132:Commerce; D006801:Humans; D007449:Investments; D012926:Social Control, Formal; D023822:Tissue Engineering / Q000191:economics* / Q000331:legislation & jurisprudence / Q000379:methods*; D057170:Translational Research, Biomedical / Q000191:economics* / Q000331:legislation & jurisprudence / Q000379:methods*